Price target
Based on analysts projections #BMRA is expected to experience a price decline over the next year.
The current average BMRA price target, as estimated by these analysts, is $0.00.
The predictions for the future BMRA stock price range from a low of $0.00 to a high of $0.00, highlighting the variability of market expectations for BMRA.
It is important to note that market fluctuations and unforeseen events can have an impact on these projections, so investors should always exercise caution and conduct thorough research before making any investment decisions.
BMRA stock forecasts by analyst
| Analyst / firm | Date | Rating | Price target | Price when posted |
|---|
There are no data to display
Biomerica (BMRA) Fundamentals Checker
Financial metrics are used to evaluate financial stability which helps analysts determine if Biomerica is undervalued compared to its fair value. A company's financial health can strongly influence the stock forecast.
Neutral
Financial Scores
Updated on: 29/11/2023
Altman Z-Score: -1.2
Piotroski Score: 4.0
ESG Score
Updated on: 29/11/2023
Environmental: 43.2
Social: 50.8
Governance: 64.6
Financial Health
Updated on: 29/11/2023
DCF: Strong Buy
ROE: Sell
ROA: Sell
Debt to equity ratio: Neutral
Price to earnings ratio: Strong Sell
Price to book ratio: Strong Buy
BMRA Discounted Cash Flow
Updated on: 29/11/2023
$0.000
Discounted Cash Flow Value
$0.000
Current Price
BMRA Revenues by Segment
Updated on: 29/11/2023
Revenue from Contract with Customer, Excluding Assessed Tax
BMRA Revenues by Region
Updated on: 29/11/2023
No available data
BMRA Notes Due
Updated on: 29/11/2023
| CIK | Exchange | Title |
|---|
There are no data to display
No social results for BMRA
BMRA Stock Forecast: Biomerica's Potential for Profitable Returns
Biomerica (BMRA) is a leading player in the medical devices market, offering innovative diagnostic solutions for a wide range of afflictions. The company's product portfolio includes an extensive range of diagnostic tests for gastrointestinal disorders, food intolerances, and infectious diseases. Biomerica is located in Irvine, California and has been around since 1971. It operates as a global biomedical company that... Read more
Promising Stock Prediction for Biomerica in the Rapidly Evolving Medical Devices Sector
The medical devices sector is one of the fastest-growing industries, driven by increasing healthcare spending and a growing aging population. The sector comprises companies that manufacture medical equipment, instruments, and devices used in diagnosis, treatment, and monitoring of health conditions. Biomerica is a leading player in the medical devices industry with its stock ticker symbol "BMRA" listed on the NASDAQ...
The stock prediction for Biomerica looks promising as it has been showing consistent growth over the past few years. In 2023 alone, its stock price surged by over 200%, outperforming its peers in the industry.
One of the factors driving Biomerica's success is the growing demand for rapid diagnostic testing amid the COVID-19 pandemic. Biomerica has developed a COVID-19 IgG/IgM Rapid Test which received Emergency Use Authorization from the U.S Food and Drug Administration (FDA) in August 2023.
Moreover, Biomerica continues to work on expanding its product line to meet changing market demands. The company recently gained FDA approval for its InFoods IBS Diagnostic Guided Therapy which uses personalized diagnostics to identify specific food triggers that cause Irritable Bowel Syndrome (IBS).
As such advancements are being made by Biomerica and other companies within the Medical Devices sector overall, it is important to keep an eye on this market as it will continue to evolve moving forward. As such changes occur, keep watchful attention towards potential impacts on stocks within this space, particularly keeping considerations towards relevant stock predictions in mind when considering whether or not to invest funds into them.">Read more
The stock prediction for Biomerica looks promising as it has been showing consistent growth over the past few years. In 2023 alone, its stock price surged by over 200%, outperforming its peers in the industry.
One of the factors driving Biomerica's success is the growing demand for rapid diagnostic testing amid the COVID-19 pandemic. Biomerica has developed a COVID-19 IgG/IgM Rapid Test which received Emergency Use Authorization from the U.S Food and Drug Administration (FDA) in August 2023.
Moreover, Biomerica continues to work on expanding its product line to meet changing market demands. The company recently gained FDA approval for its InFoods IBS Diagnostic Guided Therapy which uses personalized diagnostics to identify specific food triggers that cause Irritable Bowel Syndrome (IBS).
As such advancements are being made by Biomerica and other companies within the Medical Devices sector overall, it is important to keep an eye on this market as it will continue to evolve moving forward. As such changes occur, keep watchful attention towards potential impacts on stocks within this space, particularly keeping considerations towards relevant stock predictions in mind when considering whether or not to invest funds into them.">Read more
Biomerica (BMRA) Social Sentiments
Monitoring bullish and bearish sentiments towards Biomerica on Twitter and Stocktwits could help to forecast an upward or downward trend in Biomerica stock price.